MX2019007606A - Derivados de triazintriona y su uso como moduladores de receptor de neurotrofinas y receptor de tirosina quinasa. - Google Patents
Derivados de triazintriona y su uso como moduladores de receptor de neurotrofinas y receptor de tirosina quinasa.Info
- Publication number
- MX2019007606A MX2019007606A MX2019007606A MX2019007606A MX2019007606A MX 2019007606 A MX2019007606 A MX 2019007606A MX 2019007606 A MX2019007606 A MX 2019007606A MX 2019007606 A MX2019007606 A MX 2019007606A MX 2019007606 A MX2019007606 A MX 2019007606A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor
- sup
- modulators
- tyrosine kinases
- neurotrophin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/30—Only oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1651706 | 2016-12-21 | ||
| PCT/GB2017/053868 WO2018115891A1 (en) | 2016-12-21 | 2017-12-21 | Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019007606A true MX2019007606A (es) | 2020-07-29 |
Family
ID=60923799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007606A MX2019007606A (es) | 2016-12-21 | 2017-12-21 | Derivados de triazintriona y su uso como moduladores de receptor de neurotrofinas y receptor de tirosina quinasa. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200113910A1 (https=) |
| EP (1) | EP3558320A1 (https=) |
| JP (1) | JP2020502225A (https=) |
| KR (1) | KR20190098982A (https=) |
| CN (1) | CN110167558A (https=) |
| AU (1) | AU2017380583A1 (https=) |
| BR (1) | BR112019012709A2 (https=) |
| CA (1) | CA3046289A1 (https=) |
| IL (1) | IL267086A (https=) |
| MX (1) | MX2019007606A (https=) |
| RU (1) | RU2019120431A (https=) |
| WO (1) | WO2018115891A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52415A (fr) | 2018-02-26 | 2021-01-06 | AlzeCure Pharma AB | Dérivés de triazine pour le traitement de maladies associées à des neurotrophines |
| GB201810668D0 (en) | 2018-06-28 | 2018-08-15 | Stiftelsen Alzecure | New compounds |
| GB201912404D0 (en) * | 2019-08-29 | 2019-10-16 | AlzeCure Pharma AB | New compounds |
| CN113057957A (zh) * | 2021-03-30 | 2021-07-02 | 福建中医药大学 | 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途 |
| CN113893334A (zh) * | 2021-10-19 | 2022-01-07 | 内蒙古医科大学第二附属医院 | 基于cAMP/PKA-CREB-BDNF信号通路的七氟烷影响抑制剂及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2718799A1 (de) | 1977-04-27 | 1978-11-09 | Bayer Ag | 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer |
| KR101457027B1 (ko) * | 2009-06-09 | 2014-10-31 | 캘리포니아 캐피탈 에쿼티, 엘엘씨 | 트리아진 유도체와 이들의 치료적 용도 |
| CN103180297A (zh) * | 2009-12-11 | 2013-06-26 | 基因密码公司 | 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法 |
-
2017
- 2017-12-21 JP JP2019534090A patent/JP2020502225A/ja active Pending
- 2017-12-21 CA CA3046289A patent/CA3046289A1/en not_active Abandoned
- 2017-12-21 AU AU2017380583A patent/AU2017380583A1/en not_active Abandoned
- 2017-12-21 US US16/471,923 patent/US20200113910A1/en not_active Abandoned
- 2017-12-21 EP EP17825283.9A patent/EP3558320A1/en not_active Withdrawn
- 2017-12-21 BR BR112019012709A patent/BR112019012709A2/pt not_active Application Discontinuation
- 2017-12-21 WO PCT/GB2017/053868 patent/WO2018115891A1/en not_active Ceased
- 2017-12-21 MX MX2019007606A patent/MX2019007606A/es unknown
- 2017-12-21 KR KR1020197018642A patent/KR20190098982A/ko not_active Ceased
- 2017-12-21 CN CN201780078675.XA patent/CN110167558A/zh active Pending
- 2017-12-21 RU RU2019120431A patent/RU2019120431A/ru not_active Application Discontinuation
-
2019
- 2019-06-04 IL IL267086A patent/IL267086A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110167558A (zh) | 2019-08-23 |
| IL267086A (en) | 2019-08-29 |
| RU2019120431A (ru) | 2021-01-22 |
| BR112019012709A2 (pt) | 2019-11-26 |
| JP2020502225A (ja) | 2020-01-23 |
| RU2019120431A3 (https=) | 2021-03-09 |
| CA3046289A1 (en) | 2018-06-28 |
| WO2018115891A1 (en) | 2018-06-28 |
| EP3558320A1 (en) | 2019-10-30 |
| US20200113910A1 (en) | 2020-04-16 |
| AU2017380583A1 (en) | 2019-06-27 |
| KR20190098982A (ko) | 2019-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019007606A (es) | Derivados de triazintriona y su uso como moduladores de receptor de neurotrofinas y receptor de tirosina quinasa. | |
| EP3885344A3 (en) | Pyrimidine compounds, preparation method therefor and pharmaceutical uses thereof | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| MY159327A (en) | Jak kinase modulating quinazoline derivatives and methods of use thereof | |
| MX2014006027A (es) | Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson. | |
| SA519401541B1 (ar) | [1، 5-a] مركبات بيرازولو كيناز ret بيريدين بها استبدال كمثبطات | |
| PH12018500121A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| MX2022007975A (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos. | |
| WO2021016112A3 (en) | Non-sedating dexmedetomidine treatment regimens | |
| PH12015501326A1 (en) | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer | |
| PH12017500146B1 (en) | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof | |
| EA201291220A1 (ru) | Производные аминопиримидина в качестве модуляторов lrrk2 | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
| PH12013500880A1 (en) | Pyrazole aminopyrimidine derivatives as lrrk2 modulators | |
| MX2025002953A (es) | Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis | |
| MY206763A (en) | Piperidinyl-3-(aryloxy)propanamides and propanoates | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| MX2013002384A (es) | Compuestos quinazolina y metodos para utilizarlos. | |
| BR112022009805A2 (pt) | Derivados de piridopirimidinona como antagonistas de ahr | |
| MY201535A (en) | Therapeutic compounds | |
| WO2015048188A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
| PH12016502432A1 (en) | 1h-1,8-naphthyridin-2-ones as anti proliferative compounds |